Angel Pharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ciforadenant (CPI-444) / Corvus Pharma
Morpheus Lung, NCT03337698 / 2017-001267-21: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Checkmark Combo atezolizumab
Nov 2017 - Nov 2017: Combo atezolizumab
Active, not recruiting
1/2
675
Europe, US, RoW
Atezolizumab, Cobimetinib, RO6958688, Docetaxel, CPI-444, Pemetrexed, Carboplatin, Gemcitabine, Linagliptin, Tocilizumab, Ipatasertib, Bevacizumab, Sacituzumab Govitecan, Radiation, Evolocumab, Tiragolumab, XL092, Zanzalintinib, Camonsertib
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
09/25
11/26
NCT05501054: Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Recruiting
1/2
24
US
Ipilimumab, Yervoy, BMS-734016, MDX010, Nivolumab, BMS-936558, Opdivo, Ciforadenant
M.D. Anderson Cancer Center
Renal Cell Carcinoma
11/26
11/26
NCT03454451: CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Completed
1
117
US, RoW
CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
Corvus Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
12/22
02/23
soquelitinib (CPI-818) / Corvus Pharma
NCT06345404: Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

Recruiting
1
64
US
Soquelitinib, Placebo
Corvus Pharmaceuticals, Inc.
Atopic Dermatitis
04/25
04/25
NCT03952078: A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma

Active, not recruiting
1
151
US, RoW
CPI-818
Corvus Pharmaceuticals, Inc.
T-cell Lymphoma
04/26
04/26

Download Options